Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph? - Wikidata - wikimedia - TriplyDB

Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?

Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?

http://www.wikidata.org/entity/Q35146943

about

Reasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naïve Patients with HIV Infection: A Retrospective Cohort Analysis Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies.

P2860

Q28546795-0BC07AF0-BAE3-4DD6-91B9-00270B5FB5AE Q34536677-FAF3456E-B128-4A17-AFA4-60ABD100B205 Q36286145-016C62C5-883D-4355-A905-D2EDDE475BF5 Q40070125-DA49ABB1-6160-482B-9A63-9B6D5F9BD89B

P2860

Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?

http://www.wikidata.org/entity/Q35146943

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Incidence and determinants of ...... fricans: nevirapine's epitaph?

@ast

Incidence and determinants of ...... fricans: nevirapine's epitaph?

@en

type

label

Incidence and determinants of ...... fricans: nevirapine's epitaph?

@ast

Incidence and determinants of ...... fricans: nevirapine's epitaph?

@en

prefLabel

Incidence and determinants of ...... fricans: nevirapine's epitaph?

@ast

Incidence and determinants of ...... fricans: nevirapine's epitaph?

@en

P1433

Q35146943-C0E3A25F-9E2F-47EE-936F-E123FBB1C0A2

P1476

Q35146943-FCB3AA4B-117A-4AED-811A-EF7DC11613F0

P2093

Q35146943-5BE2DB2F-ED2A-4DF7-A321-1BF52EC2BFE8

Q35146943-60707F3B-41E7-40C0-8F86-738EE8199894

Q35146943-9A67289D-8950-422B-9497-7C83E37298B4

Q35146943-AD615D89-78F8-4FCB-9AE9-DE3BB668E6D3

P2860

Q35146943-011FB284-0E08-4340-84FF-48C70FE5BDCD

Q35146943-06DEF0C6-5636-4096-A2CA-ADCD38FEA24E

Q35146943-0916E711-287A-415F-B7A1-A70599053746

Q35146943-095FC29F-CF7C-4F23-81E4-06259BA7ED35

Q35146943-1CCC35BD-E3F0-44D0-A964-93C977A2EE7A

Q35146943-2AB81394-63CF-4830-92D7-BB8872F006A9

Q35146943-2E011841-3B7A-4E73-9709-85D15DD7B6FD

Q35146943-340D7E71-7023-4424-BF8E-CB9E1EB88EFA

Q35146943-47E38181-81CB-4AFC-9091-9DBF51CF246F

Q35146943-4C44FF93-262F-4472-888B-02DAD3C93036

P304

Q35146943-F42E24B8-9CEB-46B7-B80D-A61D0EBEE546

P31

Q35146943-4B0C42A5-A670-41B8-AD27-56F08FAF9408

P356

Q35146943-163E664F-DDA3-4060-A62D-45DCBB9F9054

P407

Q35146943-54CD7919-DB43-46F6-B85F-984491F80A45

P433

Q35146943-39A46251-DF1C-4D46-89B8-63331DDF8AB7

P478

Q35146943-85C0AED6-2B02-4171-862B-97718932363B

P50

Q35146943-9351DDE1-C8A8-40DC-8006-9F57BB566313

P577

Q35146943-10BF8AF5-69B5-4257-8A0A-02D79431E654

P5875

Q35146943-51ED1B21-EA36-4C24-9B7D-BDE37B2A09C4

P698

Q35146943-D757A782-7594-4E84-8B72-EE8DB29C69D7

P932

Q35146943-7FD29BE2-95E3-4897-B278-5C767D9DE03E

P356

JOURNAL.PONE.0094854

P1433

P1476

Incidence and determinants of ...... fricans: nevirapine's epitaph?

@en

P2093

Betty Norman

http://www.w3.org/2001/XMLSchema#string

David Chadwick

http://www.w3.org/2001/XMLSchema#string

Maame Anima Sarfo

http://www.w3.org/2001/XMLSchema#string

Richard Phillips

http://www.w3.org/2001/XMLSchema#string

P2860

Sex differences in nevirapine rash.

Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.

The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients.

Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women

Is it safe to switch between efavirenz and nevirapine in the event of toxicity?

Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA)

Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.

P304

e94854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0094854

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Fred Stephen Sarfo

P577

2014-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261609731

http://www.w3.org/2001/XMLSchema#string

P698

24728406

http://www.w3.org/2001/XMLSchema#string

P932

3984248

http://www.w3.org/2001/XMLSchema#string